Beam Therapeutics Inc.
https://beamtx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Beam Therapeutics Inc.
Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India
Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?
Gene Editing Excels As Regenerative Medicine Reaches Record Investments
Gene and cell-based therapeutics attracted the bulk of regenerative medicine investment last year, with gene-editing approaches garnering confidence following key clinical milestones, new research shows.
5 Dealmaking Trends To Watch In 2022
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
Up, Up And Away: A Comparison Of Industry R&D Spend Now Versus 10 Years Ago
Average R&D spending by the top 25 biopharma companies increased as a percent of sales from 14.4% in 2010 to 17% in 2020, according to an EY report.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Guide Therapeutics, Inc.